Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications

Tissue Antigens

Volumn 77, Issue 6, 2011, Pages 525-534

  Duquesnoy, R J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acceptable mismatch; Eplet; HLAMatchmaker; Human leukocyte antigen (HLA) epitope; Human leukocyte antigen antibody

Indexed keywords

ANTIBODY; EPITOPE; HLA ANTIGEN;

ALGORITHM; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTIGENICITY; CLINICAL ASSESSMENT; COMPUTER PROGRAM; CORNEA TRANSPLANTATION; DATA BASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOGENICITY; KIDNEY GRAFT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SERUM; THROMBOCYTE TRANSFUSION;

ALGORITHMS; BLOOD GROUP INCOMPATIBILITY; BLOOD PLATELETS; BLOOD TRANSFUSION; CORNEAL TRANSPLANTATION; EPITOPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; PHENOTYPE; PROTEIN CONFORMATION; RISK FACTORS; TRANSPLANTATION;

EID: 79956124144     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01646.x     Document Type: Review

References (68)

1. Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002: 63: 339-52.
2. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006: 67: 847-62.
3. Duquesnoy R. Clinical usefulness of HLAMatchmaker in HLA epitope matching for organ transplantation. Curr Opin Immunol 2008: 20: 594-601.
4. Duquesnoy RJ, Marrari M. HLAMatchmaker-based definition of structural HLA epitopes detected by alloantibodies. Curr Opin Organ Transpl 2009: 14: 403-9.
5. Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ and HLA-DP. Hum Immunol 2007: 68: 12-25.
6. Duquesnoy R, Mostecki J, Hariharan J, Balasz I. A structurally based epitope analysis of MICA antibody specificity patterns. Hum Immunol 2008: 69: 826-32.
7. Dankers MKA, Witvliet MD, Roelen DL et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched HLA antigens. Transplantation 2004: 128: 1236-9.
8. Goodman R, Taylor C, O'Rourke C, Lynch A, Bradley A, Key K. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitised patients awaiting kidney transplantation. Transplantation 2006: 81: 1331-6.
9. Mihaylova A, Baltadjieva D, Boneva P et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays - single-center experience. Hum Immunol 2006: 67: 787-94.
10. Kosmoliaptsis V, Bradley J, Sharples L et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008: 85: 1817-25.
11. Lomago J, Jelenik L, Zern D et al. How did a patient who types for HLA-B*4403 develop antibodies that react with HLA-B*4402? Hum Immunol 2010: 71: 176-8.
12. Duquesnoy R, Awadalla Y, Lomago J et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transpl Immunol 2008: 18: 352-60.
13. Duquesnoy RJ, Takemoto S, De Lange P, Doxiadis IIN, Schreuder GMT, Claas FHJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival. Transplantation 2003: 75: 884-9.
14. Duquesnoy RJ, Howe J, Takemoto S. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003: 75: 889-97.
15. Haririan A, Fagoaga O, Daneshvar H et al. Predictive value of HLA epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transplant 2006: 20: 226-33.
16. Laux G, Mytilineos J, Opelz G. Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation 2004: 77: 902-7.
17. Duquesnoy R, Claas F. Is the application of HLAMatchmaker relevant in kidney transplantation? (Letter to the Editor). Transplantation 2005: 79: 250-1.
18. Laux G, Mansmann U, Deufel A, Opelz G. A new epitope-based HLA-DP matching approach for cadaveric kidney transplantation. Transplantation 2003: 75: 1527-32.
19. Boehringer D, Reinhard T, Duquesnoy R et al. Beneficial effect of matching at the HLA-A and B amino-acid triplet level on rejection free survival in penetrating keratoplasty. Transplantation 2004: 77: 417-21.
20. Böhringer D, Reinhard T. Praktikabilität des HLA-matchings. Ophthalmologe 2007: 104: 219-21.
21. Böhringer D, Daub F, Schwartzkopff J et al. Operational post-keratopasty graft tolerance due to differential HLAMatchmaker matching. Mol Vis 2010: 16: 2362-7.
22. Dankers MKA, Heemskerk MHM, Duquesnoy RJ et al. HLAMatchmaker algorithm is not a suitable tool predict the alloreactive cytotoxic T lymphocyte response in vitro. Transplantation 2004: 78: 165-71.
23. Duquesnoy RJ, Haagenson M, Spellman S, Wang T, Oudshoorn M. Triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant 2008: 14: 1064-71.
24. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977: 2: 219-26.
25. Brecher ME. Technical Manual. Bethesda American Association of Blood Banks, 2005.
26. Nambiar A, Duquesnoy RJ, Adams S et al. HLAMatchmaker-driven analysis of response to HLA matched platelet transfusions in alloimmunized patients. Blood 2006: 107: 1680-7.
27. Brooks E, MacPherson B, Fung M. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008: 48: 2159-66.
28. Duquesnoy R. Structural epitope matching for HLA alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion 2008: I48: 221-7.
29. Claas FH, Gijbels Y, von Veen A et al. Selection of cross-match negative HLA-A and/or -B mismatched donors for highly sensitized patients. Transplant Proc 1989: 21: 665-6.
30. Claas FHJ, Witvliet M, Duquesnoy RJ, Persijn G, Doxiadis IIN. The acceptable mismatch program as a fast tool to transplant highly sensitized patients awaiting a post-mortal kidney: short waiting time and excellent graft outcome. Transplantation 2004: 78: 190-3.
31. Duquesnoy RJ, White LT, Fierst JW et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990: 50: 427-37.
32. Rodey GE, Revels K, Fuller TC. Epitope specificity of HLA class I alloantibodies. II. Stability of cross-reactive group antibody patterns over extended time periods. Transplantation 1997: 63: 885-93.
33. Papassavas AC, Iniotaki-Theodoraki A, Boletis J, Douramani P, Kostakis A, Stavropoulos-Giokas C. A limited number of HLA epitopes are recognized from HLA class I-specific antibodies detected in the serum of sensitized patients. Hum Immunol 2000: 61: 705-10.
34. Duquesnoy R, Marrari M. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transplant Immunol 2011 (in press).
35. Marrari M, Duquesnoy R. Why can sensitization by a HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1? Hum Immunol 2009: 70: 403-9.
36. Papassavas AC, Stavropoulos-Giokas C, Boletis J, Ioannou S, Iniotaki-Theodoraki A, Kostakis A. Definition of permissible and immunogenic HLA antigens based on epitope analysis of the HLA specific antibodies produced in sensitized patients. Eur J Immunogenet 2002: 29: 401-7.
37. Duquesnoy RJ, Witvliet MJ, Doxiadis IIN, de Fijter H, Claas FHJ. HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 2004: 7: 31-8.
38. Claas FHJ, Dankers MK, Oudshoorn M et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 2005: 14: 187-91.
39. Doxiadis IIN, Duquesnoy RJ, Claas FHJ. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005: 17: 536-40.
40. Iniotaki-Theodoraki A, Kalogeropoulou E, Apostolaki M, Doxiadis I, Stavropoulos-Giokas C. Humoral sensitization against rejected grafts: specific antibodies to graft immunogenic amino acid triplets. Transplant Proc 2004: 36: 1728-31.
41. Varnavidou-Nicolaidou A, Doxiadis II, Iniotaki-Theodoraki A et al. HLA class I donor-specific triplet antibodies detected after renal transplantation. Transplant Proc 2004: 36: 1732-4.
42. Valentini RP, Nehlsen-Cannarella SL, Gruber SA et al. Intravenous immunoglubulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Pediatr Transplant 2007: 11: 77-81.
43. Duquesnoy RJ. "Match and Treat", an effective strategy for transplanting highly sensitized pediatric transplant candidates? (Invited Editorial). Pediatr Transplant 2007: 11: 3-4.
44. El-Awar NR, Akaza T, Terasaki PI et al. Human leukocyte antigen class I epitopes: update to 103 total epitopes, including the C locus. Transplantation 2007: 84: 532-40.
45. Cai J, Terasaki PI, Mao Q et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006: 6: 2947-54.
46. Deng CT, El-Awar N, Ozawa M et al. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008: 86: 452-9.
47. Duquesnoy R, Marrari M. Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue Antigens 2009: 74: 117-33.
48. Marrari M, Duquesnoy R. Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR, -DQ and -DP antigens. Tissue Antigens 2009: 74: 134-46.
49. Adeyi OE, Girnita A, Awadalla Y et al. Serum analysis after kidney transplant nephrectomy reveals restricted antibody specificity patterns against donor HLA class I antigens. Transpl Immunol 2005: 14: 53-62.
50. Marrari M, Mostecki J, Mulder A, Balazs I, Claas F, Duquesnoy R. Human monoclonal antibody reactivity with HLA class I epitopes defined by pairs of mismatched eplets and self eplets. Transplantation 2010: 90: 1468-72.
51. Barabanova Y, Ramon D, Tambur AR. Antibodies against HLA-DQ alpha-chain and their role in organ transplantation. Hum Immunol 2009: 70: 410-8.
52. Tambur A, Leventhal JR, Friedewald J, Ramon D. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010: 90: 1117-24.
53. Davies D, Padlan E, Sheriff S. Antibody-antigen complexes. Annu Rev Biochem 1990: 59: 439-73.
54. MacCallum RM, Martin ACR, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 1996: 262: 732-45.
55. Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994: 31: 169-217.
56. Getzoff ED, Tainer JA, Lerner RA, Geysen HM. The chemistry and mechanism of antibody binding to protein antigens. Adv Immunol 1988: 43: 1-98.
57. Novotny J. Protein antigenicity: a thermodynamic approach. Mol Immunol 1991: 28: 201-8.
58. Laune D, Molina K, Ferrieres G et al. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J Biol Chem 1997: 272: 30937-44.
59. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998: 280: 1-9.
60. Van Regenmortel M. Reductionism and the search for structure-function relationships in antibody molecules. J Mol Recognit 2002: 15: 240-7.
61. Murphy K, Travers P, Walport M, Janeway C. Janeway's Immunobiology, 7th edn New York Garland Science, 2008.
62. Gaudin E, Rosado M, Agenes F, McLean A, Freitas A. B-cell homeostasis, competition, resources, and positive selection by self-antigens. Immunol Rev 2004: 197: 102-20.
63. Cancro M, Kearney J. B cell positive selection: road map to the primary repertoire. J Immunol 2004: 173: 15-9.
64. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993: 177: 999-1006.
65. Tiegs S, Russell D, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993: 177: 1009-17.
66. Reiter M, Nemazee D. Receptor editing occurs frequently during normal B cell development. J Exp Med 1998: 188: 1231-8.
67. Tze L, Baness E, Hippen K, Behrens T. Ig light chain receptor editing in anergic B cells. J Immunol 2000: 165: 6796-802.
68. Wardemann H, Hammersen J, Nussenzweig M. Human autoantibody silencing by immunoglobulin light chains. J Exp Med 2004: 200: 191-9.